Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins – Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tesseras innovations in genome engineering technologies and apply Serotinys tMDP mining and design expertise to further optimize Tesseras programmable Gene Writer proteins, capable of making diverse and directed alterations to the genome.

Were extremely excited to be working with the Tessera team, said Colin Farlow, J.D., Serotinys CEO. It provides Serotiny a unique opportunity to extend the validation of our platform and to continue to advance our efforts in discovering and developing proteins with novel function for the purpose of enhancing the therapeutic utility of next-generation genetic medicines.

Tesseras Gene Writer candidates can allow the substitution, insertion, or deletion of DNA sequences, as well as the writing of entire genes into the genome, offering the potential for a new category of genetic medicines. By partnering with Serotiny, Tessera will have the ability to identify, screen, and optimize a variety of proteins that can serve as the foundation of future Gene Writer therapies across a variety of disease states.

Tesseras mission is to cure disease by writing in the code of life and were committed to continuously innovating to improve and expand our Gene Writing platform, said Geoffrey von Maltzahn, PhD, co-founder and CEO of Tessera. Our R&D engine seeks to learn from billions of years of mobile genetic element evolution to generate novel Gene Writing systems with the ability to solve important challenges in genetic medicine. Serotinys multi-domain engineering expertise has the potential to further optimize our Gene Writer protein libraries and were delighted to partner with the Serotiny team.

Under terms of the agreement Serotiny will receive an upfront payment and is eligible for certain future consideration, contingent upon the collaboration achieving pre-specified performance thresholds.

About Serotiny

Serotiny is a pre-clinical discovery company building better gene and cell therapies through high-throughput engineering of therapeutic Multi-Domain Proteins (tMDP) such as Chimeric Antigen Receptors (CARs), CAR alternatives, accessory proteins, and next generation gene editors. At the heart of Serotinys technology is a discovery platform that harmonizes computationally aided protein design, high-throughput cellular assays, and next generation sequencing. Serotinys platform enables a cross disciplinary approach to engineering large and often unstructured multi-domain proteins, applying expertise from synthetic biology, immunology, machine learning, software engineering and bioinformatics. For more info visit http://www.serotiny.bio, or contact Colin Farlow at info@serotiny.bio.

About Tesseras Gene Writer platform

Tesseras Gene Writer proteins are based on natures genome architects, Mobile Genetic Elements (MGEs)the most abundant class of genes across the tree of life, representing approximately half of the human genome. Tessera has evaluated tens of thousands of natural and synthetic MGEs to create Gene Writer candidates in multiple categories including:

Tesseras research engine further optimizes the discovered Gene Writer candidates for efficiency, specificity, and fidelityessentially compressing eons of evolution into a few months.

About Tessera Therapeutics

Tessera Therapeutics is pioneering Gene Writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The Gene Writing platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences enterprise that conceives, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. For more information about Tessera, please visit http://www.tesseratherapeutics.com.

Read the rest here:
Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins - Business Wire